Product Dossier
JULUCA
Product Dossier for JULUCA (dolutegravir, rilpivirine, ViiV Healthcare). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: ViiV Healthcare
- Active ingredient: dolutegravir, rilpivirine
- Therapeutic area: Infectious Disease
- Related brand: DOVATO
- Related brand: TIVICAY
- Related brand: TRIUMEQ
- Same area: RETROVIR
- Same area: Savacol Antiseptic Mouth & Throat Rinse
What it is
JULUCA is a tablet containing dolutegravir 50 mg (as sodium) and rilpivirine 25 mg (as hydrochloride).
Approved indications
— Human immunodeficiency virus (HIV) infection in patients who are virologically suppressed on current treatment.
Key safety warnings
The provided sources do not contain information about key safety warnings specific to JULUCA.
Contraindications
The provided sources do not contain information about contraindications specific to JULUCA.
PBS listing
JULUCA is listed on the PBS under Section 100 (Highly Specialised Drugs Program – Community Access) with Authority Required (Streamlined) restriction on a weighted price cost-minimisation basis. The ex-manufacturer price and specific item number are not provided in the available sources.
Regulatory history
JULUCA was first registered on the ARTG on 20 June 2018. In July 2018, the PBAC recommended listing for the treatment of human immunodeficiency virus infection in patients who are virologically suppressed on current treatment.